Anixa Biosciences
Melville
About Anixa Biosciences
Anixa is a publicly-traded biotechnology company focused on harnessing the body's immune system in the fight against cancer. Anixa's therapeutic portfolio includes a cancer vaccine technology focused on the immunization against ╬▒-Lactalbumin to prevent triple negative breast cancer (TNBC), as well as a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology. The company's diagnostic portfolio consists of Cchek™, a liquid biopsy technology for early detection of solid tumors based on the body's immune response to the presence of a malignancy. Anixa continually examines emerging technologies in complementary fields for further development and commercialization.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $34.3M
- Funding stage: IPO
- Last round: Grant (Dec 2023)
- Ticker: nasdaq:ANIX
- Website: anixa.com
- Phone: 408-708-9808
Industries & Categories
Biotechnology, Finance, Market Research, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/anixa-biosciences-97972 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.